On July 25, 2020, the “National Conference of Researchers on Phase IIb Clinical Trial of antimicrobial peptide PL-5 spray in the treatment of open wound infection" was successfully held in Shenzhen, marking that the National “12th Five-Year Plan” and “13th Five-Year Plan” Mega-Projects for Innovative Drugs of China and the national category I new drug PL-5 clinical trial officially entered the acceleration phase. Antimicrobial peptide PL-5 spray has the advantages of high efficiency, broad-spectrum and low toxicity, and is the new generation of broad-spectrum anti-infective drugs.
The conference was carried out in the mode of "offline + online", with 28 clinical centers in China. The phase IIb clinical trial was led by Professor Wu Jun, from the First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital). The large sample size of clinical trial and the participation of many experts and scholars in the discussion throughout the country inspired people. Professor Wu Jun, chief researcher of the project, chairman of the Burn Surgery Branch of the Chinese Medical Association and the director of Burn Orthopedics Department of the First Affiliated Hospital of Shenzhen University, delivered a welcome speech. Professor Chen Yuxin, founder, chairman and CEO of ProteLight Pharma, directors of Guangzhou Huayin Medical Research Institute and Tigermed delivered speeches in the conference, respectively.
Professor Chen Yuxin, chairman and CEO of ProteLight Pharma introduced the situation of the company and antibacterial peptide PL-5 sprays
Professor Wu Jun from the First Affiliated Hospital of Shenzhen University introduced the clinical research plan and answered the related questions
In the conference, Professor Wu Jun and all the participating experts in the conference had a full and passionate discussion about the clinical research plan, and the researchers who could not attend the conference due to the COVID-19 also put forward their own opinions and suggestions online.
Group photo of guests